Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0843010/Postmenopausal-Vaginal-Atrophy-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Postmenopausal Vaginal Atrophy Therapeutics market. The report identifies the key trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Postmenopausal Vaginal Atrophy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Postmenopausal Vaginal Atrophy Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postmenopausal Vaginal Atrophy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Postmenopausal Vaginal Atrophy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Postmenopausal Vaginal Atrophy Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Postmenopausal Vaginal Atrophy Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Postmenopausal Vaginal Atrophy Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Postmenopausal Vaginal Atrophy Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Postmenopausal Vaginal Atrophy Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 7
2.3 Etiology 7
2.4 Pathophysiology 8
2.5 Signs and Symptoms 8
2.6 Diagnosis 8
2.6.1 Laboratory Diagnosis Tests 8
2.7 Treatment and Management Options 9
2.7.1 Vaginal Cream 9
2.7.2 Estradiol Ring 9
2.7.3 Vaginal Tablet 9
2.8 GlobalData Pipeline Report Guidance 10
3 Postmenopausal Vaginal Atrophy Therapeutics - Market Characterization 11
3.1 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Global 11
3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Global 13
3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The US 14
3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The US 15
3.5 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - France 16
3.6 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - France 17
3.7 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Germany 18
3.8 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Germany 19
3.9 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Italy 20
3.10 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Italy 21
3.11 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Spain 22
3.12 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Spain 23
3.13 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The UK 24
3.14 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The UK 25
3.15 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Japan 26
3.16 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Japan 27
3.17 Drivers and Barriers for the Postmenopausal Vaginal Atrophy Therapeutics Market 28
3.17.1 Drivers for the Postmenopausal Vaginal Atrophy Therapeutics Market 28
3.17.2 Barriers to the Postmenopausal Vaginal Atrophy Therapeutics Market 28
3.18 Opportunity and Unmet Need Analysis 29
3.19 Key Takeaway 29
4 Postmenopausal Vaginal Atrophy Therapeutics - Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profiles for the Major Marketed Products in the Postmenopausal Vaginal Atrophy Therapeutics Market 31
4.3.1 Vaginal Cream 31
4.3.2 Estrace 31
4.3.3 Premarin 31
4.3.4 Vaginal Ring 32
4.3.5 Estring 32
4.3.6 Femring 33
4.3.7 Vaginal Tablet 34
4.3.8 Vagifem 34
4.4 Key Takeaway 35
5 Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Postmenopausal Vaginal Atrophy Therapeutics Pipeline - Pipeline by Phase of Development 36
5.3.1 Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline 36
5.3.2 Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline 37
5.3.3 Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline 37
5.3.4 Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline 37
5.3.5 Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase 37
5.3.6 Technology Trends Analytic Framework 38
5.4 Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Mechanism of Action 40
5.5 Postmenopausal Vaginal Atrophy Therapeutics - Promising Drugs under Clinical Development 40
5.6 Molecule Profile for Promising Drugs under Clinical Development 41
5.6.1 Ophena (ospemifene) 41
5.6.2 Vaginorm (dehydroepiandrosterone) 41
5.7 Key Takeaway 42
6 Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials Mapping 43
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 43
6.2 Clinical Trials by Phase 44
6.3 Clinical Trials by Trial Status 45
6.4 Prominent Sponsors 46
6.5 Clinical Trials by Overall Sponsors 47
6.6 Top Companies Participating in Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials 48
7 Postmenopausal Vaginal Atrophy Therapeutics - Strategic Assessment 49
7.1 Key Events Impacting the Future Market 49
7.2 Postmenopausal Vaginal Atrophy Therapeutics - Implications for Future Market Competition 50
8 Postmenopausal Vaginal Atrophy Therapeutics - Future Players 51
8.1 Introduction 51
8.2 Company Profiles 51
8.2.1 Bionovo, Inc. (Bionovo) 51
8.2.2 QuatRx Pharmaceutical Company 53
8.2.3 Shionogi & Co. 53
8.2.4 EndoCeutics, Inc 54
8.2.5 Bayer AG 54
8.2.6 Other Companies in Postmenopausal Vaginal Atrophy Therapeutics Market 55
9 Postmenopausal Vaginal Atrophy Therapeutics - Appendix 56
9.1 Market Definitions 56
9.2 Acronyms 56
9.3 Methodology 56
9.3.1 Coverage 57
9.3.2 Secondary Research 57
9.3.3 Forecasting 57
9.3.4 Primary Research 60
9.3.5 Expert Panel Validation 60
9.4 Contact Us 60
9.5 Disclaimer 60
9.6 Bibliography 61
List of Tables
Table 1: Postmenopausal Vaginal Atrophy Prevalence in The US, EU5 and Japan 7
Table 2: Treatment Options for Postmenopausal Vaginal Atrophy 9
Table 3: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011 12
Table 4: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019 13
Table 5: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011 14
Table 6: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019 15
Table 7: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011 16
Table 8: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019 17
Table 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011 18
Table 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2010-2019 19
Table 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011 20
Table 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019 21
Table 13: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011 22
Table 14: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019 23
Table 15: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011 24
Table 16: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019 25
Table 17: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011 26
Table 18: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019 27
Table 19: Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline, 2011 36
Table 20: Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline, 2011 37
Table 21: Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline, 2011 37
Table 22: Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline, 2011 37
Table 23: Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase, 2011 37
Table 24: Postmenopausal Vaginal Atrophy Therapeutics - Most Promising Drugs Under Clinical Development, 2011 40
Table 25: Postmenopausal Vaginal Atrophy Therapeutics Market - Clinical Trials by Country, 2011 43
Table 26: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011 44
Table 27: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011 45
Table 28: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011 46
Table 29: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011 47
Table 30: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 48
Table 31 Bionovo Inc., Women's Healthcare Pipeline, 2011 52
Table 32: QuatRx Pharmaceuticals Company, Women's Healthcare Pipeline, 2011 53
Table 33: Shionogi Pharmaceuticals - Women's Healthcare Pipeline, 2011 53
Table 34: EndoCeutics - Women's Healthcare Pipeline, 2011 54
Table 35 Bayer AG - Women's Healthcare Pipeline, 2011 55
Table 36: Postmenopausal Vaginal Atrophy Therapeutics Market - Future Players 55
List of Figures
Figure 1: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011 11
Figure 2: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019 13
Figure 3: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011 14
Figure 4: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019 15
Figure 5: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011 16
Figure 6: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019 17
Figure 7: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011 18
Figure 8: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2011-2019 19
Figure 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011 20
Figure 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019 21
Figure 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011 22
Figure 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019 23
Figure 13: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011 24
Figure 14: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019 25
Figure 15: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011 26
Figure 16: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019 27
Figure 17: Opportunity and Unmet Need in the Postmenopausal Vaginal Atrophy Therapeutics Market, 2011 29
Figure 18: Postmenopausal Vaginal Atrophy Therapeutics - Strategic Competitor Assessment, 2011 30
Figure 19: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Phase of Development, 2011 36
Figure 20: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework, 2011 38
Figure 21: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework - Description, 2011 39
Figure 22: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Mechanism of Action, 2011 40
Figure 23: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Country, 2011 43
Figure 24: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011 44
Figure 25: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011 45
Figure 26: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011 46
Figure 27: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011 47
Figure 28: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 48
Figure 29: Postmenopausal Vaginal Atrophy Therapeutics Market - Drivers and Barriers, 2011 49
Figure 30: Implications for Future Market Competition in the Postmenopausal Vaginal Atrophy Market, 2011 50
Figure 31: Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Company, 2011 51
Figure 32: GlobalData Market Forecasting Model 59
Companies mentioned
Bionovo, Inc. (Bionovo)
QuatRx Pharmaceutical Company
Shionogi & Co.
EndoCeutics, Inc
Bayer AG
To order this report:
Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article